VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
HLNHaleon plc
$8.96$39.9B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

HLN logoHaleon plc(HLN)Earnings, Financials & Key Ratios

HLN•NYSE
18.7× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryConsumer health and OTC self-care
AboutHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.Show more
  • Revenue$10.79B-4.0%
  • EBITDA$2.77B+15.4%
  • Net Income$1.63B+13.1%
  • EPS (Diluted)0.36+12.5%
  • Gross Margin64.77%+4.7%
  • EBITDA Margin25.7%+20.2%
  • Operating Margin22.44%+14.3%
  • Net Margin15.11%+17.7%
  • ROE9.98%+14.0%

HLN Key Insights

Haleon plc (HLN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 8/9
  • ✓FCF machine: 18.3% free cash flow margin
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Healthy 5Y average net margin of 12.3%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when HLN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

HLN Price & Volume

Haleon plc (HLN) stock price & volume — 10-year historical chart

Loading chart...

HLN Growth Metrics

Haleon plc (HLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years1.75%
3 Years-0.21%
TTM10.69%

Profit CAGR

10 Years-
5 Years7.33%
3 Years15.43%
TTM50.17%

EPS CAGR

10 Years-
5 Years8.45%
3 Years14.47%
TTM53.28%

Return on Capital

10 Years6.06%
5 Years6.87%
3 Years7.64%
Last Year8.62%

HLN Recent Earnings

Haleon plc (HLN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 6/12 qtrs (60%)
Q1 2026Latest
Feb 25, 2026
Metric
Actual
Est
EPS
$0.26+3.4%
$0.25
Rev
$7.5B-0.8%
$7.6B
Q4 2025
Oct 30, 2025
Metric
Actual
Est
EPS
$0.14-42.8%
$0.24
Rev
$7.5B+171.9%
$2.8B
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$0.08-67.3%
$0.24
Rev
$7.3B+162.4%
$2.8B
Q1 2025
Feb 27, 2025
Metric
Actual
Est
EPS
$0.05-99.8%
$25.25
Rev
$7.1B+161.2%
$2.7B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 25, 2026
$0.26vs $0.25+3.4%
$7.5Bvs $7.6B-0.8%
Q4 2025Oct 30, 2025
$0.14vs $0.24-42.8%
$7.5Bvs $2.8B+171.9%
Q3 2025Aug 7, 2025
$0.08vs $0.24-67.3%
$7.3Bvs $2.8B+162.4%
Q1 2025Feb 27, 2025
$0.05vs $25.25-99.8%
$7.1Bvs $2.7B+161.2%
Based on last 12 quarters of dataView full earnings history →

HLN Peer Comparison

Haleon plc (HLN) competitors in Consumer health and OTC self-care — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
KVUE logoKVUEKenvue Inc.Direct Competitor34.79B18.1223.84-2.14%10.61%15.18%0.79
CHD logoCHDChurch & Dwight Co., Inc.Direct Competitor22.65B95.6431.671.57%11.81%17.45%0.55
PG logoPGThe Procter & Gamble CompanyDirect Competitor351.4B150.3823.100.29%14.66%23.78%0.68
CL logoCLColgate-Palmolive CompanyDirect Competitor71.79B89.4834.021.4%10.46%251.59%21.88
PBH logoPBHPrestige Consumer Healthcare Inc.Direct Competitor2.23B46.9712.01-4.31%17.48%10.29%0.55
JNJ logoJNJJohnson & JohnsonProduct Competitor550.4B228.3939.454.3%27.26%31.69%0.51
NVS logoNVSNovartis AGProduct Competitor280.64B147.0820.465.97%24.14%31.42%0.80
GSK logoGSKGSK plcProduct Competitor101.9B50.676.864.11%19.19%31.48%1.11

Compare HLN vs Peers

Haleon plc (HLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KVUE

Most directly comparable listed peer for HLN.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare HLN against a more recognizable public peer.

Peer Set

Compare Top 5

vs KVUE, CHD, PG, CL

HLN Income Statement

Haleon plc (HLN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue
8.48B9.89B9.54B10.86B11.3B11.23B10.79B
Revenue Growth %
-16.65%-3.51%13.76%4.09%-0.61%-3.96%
Cost of Goods Sold
3.68B3.98B3.6B4.28B4.34B4.29B3.8B
COGS % of Revenue
43.37%40.25%37.66%39.43%38.41%38.15%35.23%
Gross Profit
4.8B▲ 0%
5.91B▲ 23.1%
5.95B▲ 0.7%
6.58B▲ 10.5%
6.96B▲ 5.8%
6.95B▼ 0.2%
6.99B▲ 0.6%
Gross Margin %
56.63%59.75%62.34%60.57%61.59%61.85%64.77%
Gross Profit Growth %
-23.07%0.68%10.54%5.84%-0.19%0.57%
Operating Expenses
3.9B4.31B4.31B4.75B4.96B4.74B4.57B
OpEx % of Revenue
46.05%43.59%45.18%43.77%43.93%42.21%42.33%
Selling, General & Admin
3.6B4.22B3.79B4.04B4.29B4.33B4.26B
SG&A % of Revenue
42.41%42.66%39.74%37.18%37.94%38.57%39.47%
Research & Development
292M304M257M300M311M298M308.1M
R&D % of Revenue
3.44%3.07%2.69%2.76%2.75%2.65%2.86%
Other Operating Expenses
17M-212M262M415M366M111M0
Operating Income
897M▲ 0%
1.6B▲ 78.1%
1.64B▲ 2.5%
1.82B▲ 11.4%
2B▲ 9.4%
2.21B▲ 10.5%
2.42B▲ 9.7%
Operating Margin %
10.58%16.15%17.16%16.81%17.66%19.64%22.44%
Operating Income Growth %
-78.15%2.5%11.42%9.37%10.52%9.74%
EBITDA
1.16B1.9B1.91B2.11B2.31B2.4B2.77B
EBITDA Margin %
13.64%19.24%19.97%19.45%20.39%21.38%25.7%
EBITDA Growth %
-64.48%0.16%10.81%9.14%4.21%15.44%
D&A (Non-Cash Add-back)
260M305M268M287M309M196M352.11M
EBIT
912M1.61B1.94B1.9B2.04B2.32B2.42B
Net Interest Income
-2.55M-7.69M-3M-278.38M-400M-339M-256.26M
Interest Income
25.51M17.95M13M68.98M14M55M76.29M
Interest Expense
28.07M25.65M16M347.36M414M394M332.55M
Other Income/Expense
-11M-7M-2M-207M-368M-296M-315.92M
Pretax Income
886M▲ 0%
1.59B▲ 79.6%
1.64B▲ 2.8%
1.62B▼ 1.1%
1.63B▲ 0.6%
1.91B▲ 17.3%
2.1B▲ 10.2%
Pretax Margin %
10.45%16.08%17.14%14.9%14.4%17%19.51%
Income Tax
199M410M197M499M517M435M461.66M
Effective Tax Rate %
22.46%25.77%12.04%30.84%31.76%22.77%21.93%
Net Income
655M▲ 0%
1.15B▲ 74.8%
1.39B▲ 21.4%
1.06B▼ 23.7%
1.05B▼ 1.0%
1.44B▲ 37.5%
1.63B▲ 13.1%
Net Margin %
7.72%11.58%14.56%9.76%9.28%12.84%15.11%
Net Income Growth %
-74.81%21.4%-23.74%-1.04%37.46%13.07%
Net Income (Continuing)
687M1.18B1.44B1.12B1.11B1.48B1.64B
Discontinued Operations
0000000
Minority Interest
91M111M125M126M123M58M58.9M
EPS (Diluted)
0.14▲ 0%
0.24▲ 71.4%
0.30▲ 25.0%
0.24▼ 20.0%
0.24▲ 0.0%
0.32▲ 33.3%
0.36▲ 12.5%
EPS Growth %
-71.43%25%-20%0%33.33%12.5%
EPS (Basic)
0.140.240.300.240.240.320.36
Diluted Shares Outstanding
4.62B4.62B4.62B4.62B4.63B4.59B4.51B
Basic Shares Outstanding
4.62B4.62B4.62B4.62B4.63B4.57B4.48B
Dividend Payout Ratio
175.88%207.07%82.59%253.02%36.99%39.53%36.71%

HLN Balance Sheet

Haleon plc (HLN) balance sheet — assets, liabilities & shareholders' equity

MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets
5.81B5.01B5.25B4.06B4.82B5.72B4.54B
Cash & Short-Term Investments
340M334M414M684M1.04B2.25B1.32B
Cash Only
340M334M414M684M1.04B2.19B1.32B
Short-Term Investments
0000055M0
Accounts Receivable
3.99B1.35B3.83B1.49B1.35B1.9B2.12B
Days Sales Outstanding
171.9149.74146.2749.9943.6661.8771.7
Inventory
1.21B949M951M1.35B1.41B1.19B1.02B
Days Inventory Outstanding
120.1886.9996.55114.93118.39101.3798.26
Other Current Assets
237M2.32B5M434M907M223M77.86M
Total Non-Current Assets
29.9B29.12B29.2B30.76B29.24B28.6B28.03B
Property, Plant & Equipment
1.62B1.6B1.66B1.9B1.9B1.92B1.99B
Fixed Asset Turnover
5.23x6.17x5.74x5.72x5.94x5.85x5.41x
Goodwill
8.17B8.27B8.25B8.4B8.32B8.2B0
Intangible Assets
19.84B18.95B18.95B20.04B18.54B18.01B0
Long-Term Investments
3M023M44M65M82M75.87M
Other Non-Current Assets
10M51M8M157M415M383M104.82M
Total Assets
35.71B▲ 0%
34.13B▼ 4.4%
34.45B▲ 0.9%
34.81B▲ 1.1%
34.05B▼ 2.2%
34.31B▲ 0.8%
32.57B▼ 5.1%
Asset Turnover
0.24x0.29x0.28x0.31x0.33x0.33x0.33x
Asset Growth %
--4.43%0.94%1.06%-2.18%0.76%-5.08%
Total Current Liabilities
4.27B4.01B4.24B4.37B4.64B5.81B4.92B
Accounts Payable
1.9B1.83B1.58B1.83B1.85B1.97B3.72B
Days Payables Outstanding
188.36167.47160.32156.45155.97168.06357.57
Short-Term Debt
481M348M874M393M608M1.44B834.53M
Deferred Revenue (Current)
7M11M11M23M000
Other Current Liabilities
913M958M1.43B1.61B1.57B693M99.82M
Current Ratio
1.36x1.25x1.24x0.93x1.04x0.98x0.92x
Quick Ratio
1.08x1.01x1.01x0.62x0.73x0.78x0.71x
Cash Conversion Cycle
103.73-30.7482.518.466.08-4.83-187.61
Total Non-Current Liabilities
4.03B3.89B3.73B13.99B12.69B12.28B11.19B
Long-Term Debt
0009.89B8.71B8.54B7.76B
Capital Lease Obligations
121M105M87M117M89M73M0
Deferred Tax Liabilities
3.51B03.36B3.6B3.49B3.35B3.22B
Other Non-Current Liabilities
03.79B0384M424M311M217.62M
Total Liabilities
8.3B7.91B7.97B18.36B17.33B18.09B16.12B
Total Debt
642M487M991M10.44B9.46B10.1B8.59B
Net Debt
302M153M577M9.76B8.41B7.91B7.27B
Debt / Equity
0.02x0.02x0.04x0.63x0.57x0.62x0.52x
Debt / EBITDA
0.55x0.26x0.52x4.94x4.10x4.21x3.10x
Net Debt / EBITDA
0.26x0.08x0.30x4.62x3.65x3.29x2.62x
Interest Coverage
31.96x62.31x102.38x5.25x4.82x5.60x7.28x
Total Equity
27.41B▲ 0%
26.22B▼ 4.3%
26.48B▲ 1.0%
16.46B▼ 37.9%
16.73B▲ 1.7%
16.22B▼ 3.0%
16.46B▲ 1.4%
Equity Growth %
--4.34%0.98%-37.85%1.65%-3.02%1.42%
Book Value per Share
5.945.685.733.563.613.543.65
Total Shareholders' Equity
27.32B26.11B26.36B16.33B16.61B16.17B16.4B
Common Stock
1M1M1M92M92M91M89.84M
Retained Earnings
5.11B37.76B37.99B26.73B27.47B27.27B27.8B
Treasury Stock
00000-116M0
Accumulated OCI
1.37B-11.65B-11.63B1.2B-10.96B00
Minority Interest
91M111M125M126M123M58M58.9M

HLN Cash Flow Statement

Haleon plc (HLN) cash flow — operating, investing & free cash flow history

MetricDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations
786M1.41B1.36B2.06B2.1B2.3B2.29B
Operating CF Margin %
9.27%14.22%14.21%19%18.58%20.48%21.19%
Operating CF Growth %
-79.01%-3.62%52.14%1.79%9.57%-0.66%
Net Income
687M1.18B1.39B1.12B1.3B1.44B1.63B
Depreciation & Amortization
260M305M268M287M309M324M352.11M
Stock-Based Compensation
58M63M59M78M88M102M0
Deferred Taxes
199M0197M62M000
Other Non-Cash Items
43M-157M-406M336M506.04M385M52.82M
Working Capital Changes
-461M15M-152M181M-107M48M250.39M
Change in Receivables
-57M18M14M-85M38M-312M-63.58M
Change in Inventory
232M130M-17M-292M-131M216M130.09M
Change in Payables
-256M140M41M387M112M0122.26M
Cash from Investing
291M1.03B-33M-8.78B-134M528M-567.29M
Capital Expenditures
-243M-318M-298M-328M-234M-250M-403.95M
CapEx % of Revenue
2.87%3.21%3.12%3.02%2.07%2.23%3.74%
Acquisitions
120M241M112M9.21B-71M0-157.47M
Investments
-------
Other Investing
142M853M165M-9.16B171M778M0
Cash from Financing
-925M-2.44B-1.24B6.91B-1.57B-1.54B-2.55B
Debt Issued (Net)
1M28M8M9.49B-553M592M-1.28B
Equity Issued (Net)
0000-1000K-1000K-1000K
Dividends Paid
-1.15B-2.37B-1.15B-2.68B-388M-570M-598.59M
Share Repurchases
0000-38M-121M-639.67M
Other Financing
226M-94M-96M107M-589M-1.44B-39.12M
Net Change in Cash
138M▲ 0%
-6M▼ 104.3%
82M▲ 1466.7%
205M▲ 150.0%
383M▲ 86.8%
1.21B▲ 216.7%
-769.66M▼ 163.5%
Free Cash Flow
543M▲ 0%
1.09B▲ 100.6%
1.06B▼ 2.8%
1.74B▲ 64.0%
1.76B▲ 1.7%
2.05B▲ 16.3%
1.97B▼ 3.9%
FCF Margin %
6.4%11.01%11.08%15.98%15.61%18.26%18.27%
FCF Growth %
-100.55%-2.85%63.99%1.67%16.27%-3.91%
FCF per Share
0.120.240.230.380.380.450.44
FCF Conversion (FCF/Net Income)
1.20x1.23x0.98x1.95x2.00x1.60x1.40x
Interest Paid
00000360M0
Taxes Paid
0000000

HLN Key Ratios

Haleon plc (HLN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025
Return on Equity (ROE)
2.39%4.27%5.27%4.94%6.32%8.75%9.98%
Return on Invested Capital (ROIC)
2.43%4.43%4.6%5.14%5.83%6.72%7.59%
Gross Margin
56.63%59.75%62.34%60.57%61.59%61.85%64.77%
Net Margin
7.72%11.58%14.56%9.76%9.28%12.84%15.11%
Debt / Equity
0.02x0.02x0.04x0.63x0.57x0.62x0.52x
Interest Coverage
31.96x62.31x102.38x5.25x4.82x5.60x7.28x
FCF Conversion
1.20x1.23x0.98x1.95x2.00x1.60x1.40x
Revenue Growth
-16.65%-3.51%13.76%4.09%-0.61%-3.96%
Related:HLN Dividend History·HLN Revenue History·HLN Price History·HLN P/E History·HLN Financial Ratios·HLN Institutional Holders

HLN Frequently Asked Questions

Haleon plc (HLN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Haleon plc (HLN) reported $22.01B in revenue for fiscal year 2025. This represents a 160% increase from $8.48B in 2019.

Haleon plc (HLN) saw revenue decline by 4.0% over the past year.

Yes, Haleon plc (HLN) is profitable, generating $3.18B in net income for fiscal year 2025 (15.1% net margin).

Dividend & Returns

Yes, Haleon plc (HLN) pays a dividend with a yield of 1.97%. This makes it attractive for income-focused investors.

Haleon plc (HLN) has a return on equity (ROE) of 10.0%. This is below average, suggesting room for improvement.

Haleon plc (HLN) generated $3.12B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in HLN back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

How much would $100/month in HLN be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →